Form 4: RxSight Director Julie Andrews Boosts Equity Stake with RSU Grant

RxSight, Inc. Director Julie Andrews has acquired 10,752 Restricted Stock Units (RSUs), increasing her beneficial ownership in the company to 41,039 shares.

Summary

• Julie Andrews, a Director at RxSight, Inc. (RXST), reported the acquisition of 10,752 Restricted Stock Units (RSUs) on June 3, 2025.
• Each RSU represents a contingent right to receive one share of RxSight, Inc. Common Stock.
• Following this transaction, Ms. Andrews' total beneficial ownership in RxSight, Inc. common stock stands at 41,039 shares.
• The RSUs are subject to a vesting schedule where 100% will vest on the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date immediately prior to the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Ms. Andrews' continued service as an Outside Director as defined in the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their equity stake, aligning their interests with shareholders, which is generally viewed favorably. This is a routine compensation event, not indicative of extraordinary news, hence not a perfect 10.

Positives

• A director's acquisition of additional equity, even through a grant, generally signals confidence in the company's future prospects and aligns management's interests with those of shareholders.
• The increase in beneficial ownership by a director strengthens the alignment between the board and shareholder value creation.

Risks

• The vesting of the 10,752 Restricted Stock Units is contingent on Julie Andrews' continued service as an Outside Director, meaning the shares are not immediately owned and could be forfeited if service ceases before vesting.

Future Outlook

The acquired Restricted Stock Units are expected to vest on the earlier of June 3, 2026 (one-year anniversary of grant) or the date immediately prior to the next annual meeting of stockholders, provided the director continues her service.

Industry Context

This Form 4 filing represents a routine equity compensation grant to a director, a common practice across publicly traded companies to incentivize and align the interests of board members with long-term shareholder value. Such grants are standard components of director compensation packages in the medical device or ophthalmology industry, where RxSight operates.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns the director's financial interests more closely with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The Restricted Stock Units will vest on the earlier of June 3, 2026, or the day before the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Beneficial Ownership, RxSight, RXST